BRPI0921342A2 - glicoproteínas tendo propriedades de mobilização de lipídeos e aplicações terapêuticas das mesmas - Google Patents

glicoproteínas tendo propriedades de mobilização de lipídeos e aplicações terapêuticas das mesmas

Info

Publication number
BRPI0921342A2
BRPI0921342A2 BRPI0921342A BRPI0921342A BRPI0921342A2 BR PI0921342 A2 BRPI0921342 A2 BR PI0921342A2 BR PI0921342 A BRPI0921342 A BR PI0921342A BR PI0921342 A BRPI0921342 A BR PI0921342A BR PI0921342 A2 BRPI0921342 A2 BR PI0921342A2
Authority
BR
Brazil
Prior art keywords
glycoproteins
therapeutic applications
lipid mobilization
mobilization properties
properties
Prior art date
Application number
BRPI0921342A
Other languages
English (en)
Inventor
J Tisdale Michael
Russell Steven
Original Assignee
Univ Aston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aston filed Critical Univ Aston
Publication of BRPI0921342A2 publication Critical patent/BRPI0921342A2/pt
Publication of BRPI0921342B1 publication Critical patent/BRPI0921342B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
BRPI0921342-2A 2008-11-07 2009-11-07 Uso de uma zn-alfa 2 -glicoproteína junto com insulina ou sr59230a na preparação de uma formulação para tratamento de diabetes ou obesidade em um indivíduo BRPI0921342B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11262308P 2008-11-07 2008-11-07
US61/112,623 2008-11-07
US25302309P 2009-10-19 2009-10-19
US61/253,023 2009-10-19
PCT/IB2009/007373 WO2010052563A2 (en) 2008-11-07 2009-11-07 Glycoproteins having lipid mobilizing properties and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
BRPI0921342A2 true BRPI0921342A2 (pt) 2017-06-06
BRPI0921342B1 BRPI0921342B1 (pt) 2022-02-01

Family

ID=41668450

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921342-2A BRPI0921342B1 (pt) 2008-11-07 2009-11-07 Uso de uma zn-alfa 2 -glicoproteína junto com insulina ou sr59230a na preparação de uma formulação para tratamento de diabetes ou obesidade em um indivíduo

Country Status (11)

Country Link
US (7) US20100173829A1 (pt)
EP (1) EP2355838B1 (pt)
JP (6) JP2012508222A (pt)
KR (1) KR20110100210A (pt)
CN (1) CN102271701A (pt)
AU (2) AU2009312539A1 (pt)
BR (1) BRPI0921342B1 (pt)
CA (1) CA2743026C (pt)
ES (1) ES2525009T3 (pt)
IL (1) IL212695A0 (pt)
WO (1) WO2010052563A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068400A (zh) * 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
JP6010281B2 (ja) * 2011-03-03 2016-10-19 株式会社カネカ 筋肉増量剤
CN102288601B (zh) * 2011-05-16 2012-12-12 中国药科大学 一种肌球蛋白atp酶活性微量测定方法及其应用
CN102552912A (zh) * 2012-01-30 2012-07-11 林曙光 β3肾上腺素受体阻滞剂的抗肿瘤用途
US20150202259A1 (en) 2012-07-31 2015-07-23 Aston University Targeted oesophageal administration of zn-alpha2-glycoproteins (zag), methods and formulations thereof
KR102028245B1 (ko) * 2016-04-06 2019-10-04 연세대학교 산학협력단 피부 건조증 또는 피부 장벽 개선용 조성물 및 항알러지 조성물
US11213567B2 (en) * 2017-09-29 2022-01-04 L&C Bio Co., Ltd. ZAG-derived peptide and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308178D0 (en) * 1993-04-21 1993-06-02 Smithkline Beecham Plc Novel compounds
ATE154935T1 (de) * 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
US5480908A (en) * 1993-12-13 1996-01-02 American Cyanamid Company β3 -adrenergic agents benzodioxole dicarboxylates and their use in pharmaceutical compositions
ES2094687B1 (es) * 1994-08-02 1997-12-16 S A L V A T Lab Sa Combinacion farmaceutica contra la obesidad o el sobrepeso.
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
GB9811465D0 (en) * 1998-05-29 1998-07-29 Tisdale Michael J Glycoproteins having lipid mobilising properties and therapeutic applications thereof
EP1238973A4 (en) * 1999-12-16 2003-01-22 Asahi Chemical Ind NEW SUBSTITUTED TRICYCLIC COMPOUNDS
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
AUPQ981700A0 (en) * 2000-09-01 2000-09-28 Metabolic Pharmaceuticals Limited Product and method for control of obesity
ES2295415T3 (es) * 2001-10-05 2008-04-16 Serono Genetics Institute S.A. Fragmentos de la glicoproteina zn-alfa2 humana y su uso en metodos de tratamiento de la obesidad.
JP2006096666A (ja) * 2002-10-31 2006-04-13 Kaneka Corp 選択的ヒトβ３アドレナリン受容体アゴニスト剤
WO2004056777A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
AU2006206573B9 (en) * 2005-01-19 2011-09-29 Merck Sharp & Dohme Corp. Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
RU2008119687A (ru) * 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
JP2020122563A (ja) * 2019-01-31 2020-08-13 日本電産株式会社 可撓性外歯歯車および波動歯車装置

Also Published As

Publication number Publication date
JP2012508222A (ja) 2012-04-05
US20160220635A1 (en) 2016-08-04
US20240000888A1 (en) 2024-01-04
JP2022068320A (ja) 2022-05-09
CA2743026C (en) 2023-01-03
CN102271701A (zh) 2011-12-07
IL212695A0 (en) 2011-07-31
BRPI0921342B1 (pt) 2022-02-01
JP2015013872A (ja) 2015-01-22
US20100173829A1 (en) 2010-07-08
US20140243259A1 (en) 2014-08-28
EP2355838A2 (en) 2011-08-17
AU2016204169B2 (en) 2018-02-01
KR20110100210A (ko) 2011-09-09
CA2743026A1 (en) 2010-05-14
WO2010052563A2 (en) 2010-05-14
US20180339019A1 (en) 2018-11-29
ES2525009T3 (es) 2014-12-17
US20200330554A1 (en) 2020-10-22
JP2020172540A (ja) 2020-10-22
JP2017002069A (ja) 2017-01-05
US20210315969A1 (en) 2021-10-14
WO2010052563A3 (en) 2010-09-16
AU2016204169A1 (en) 2016-07-14
JP2019116487A (ja) 2019-07-18
AU2009312539A1 (en) 2010-05-14
EP2355838B1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
BRPI0822064A2 (pt) Dispositivos de imageamento fotoacústico e métodos de imageamento
CY2015013I1 (el) Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
BRPI0820882A2 (pt) Dispositivos e métodos de estimulação de dermátomo
HRP20170165T1 (hr) Onkolitički adenovirusni vektori i metode i uporabe u vezi s time
BRPI1014160A2 (pt) Formulações de nanopartículas e aplicações das mesmas
BRPI0913201A8 (pt) menus com translucidez e visualização ao vivo
BRPI0908980A2 (pt) Dispositivo de iluminação e dispositivo de exibição tendo o mesmo
EP2352816A4 (en) HUMAN TEMPORARY CELLS
BRPI0906936A2 (pt) Uso de canabinóide canabidiol e canabinóide tetraidrocanabivarina
BRPI0807525A2 (pt) Dispositivo endo-cirúrgico e método
DK3459558T3 (da) Glycoproteiner med lipidmobiliserende egenskaber og terapeutiske anvendelser deraf
FI20075881L (fi) Lääketieteellinen väline ja sen valmistus
BRPI1009847A2 (pt) conectores médicos e métodos de uso
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
FI20085334A0 (fi) Harjoitusmenetelmä ja -järjestelmä
BRPI0907064A2 (pt) "métodos e sistemas"
BR112012007861A2 (pt) dispositivos médicos e suas bombas
EP2479216A4 (en) EMULSION AND MOLDING SOLVENT WITH THE EMULSION
BRPI0816789A2 (pt) Goji e inflamação
BRPI0919903A2 (pt) dispositivo de mobilização corporal e utilização do dispositivo
BRPI0818766A2 (pt) N-fenil-pirrolidinilmetilpirrolidinamidas substituídas e uso terapêutico das mesmas
BRPI1012257A2 (pt) "fototransitor e dispositivo de exibição incluindo o mesmo"
DK2252688T3 (da) Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf
EP2242145A4 (en) Terminal joining structure and terminal joining method

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.